检索结果-南通市图书馆

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

引用

World Journal of Hepatology 2017年第5期9卷 252-262页

作者： Satoshi Yamagiwa Toru Ishikawa Nobuo Waguri Soichi Sugitani Hiroto Wakabayashi Shogo Ohkoshi Takashi Tsukishiro Toru Takahashi Toshiaki Watanabe Shuji Terai Division of Gastroenterology and Hepatology Niigata University Graduate School of Medical and Dental Sciences Department of Gastroenterology and Hepatology Saiseikai Niigata Daini Hospital Department of Gastroenterology and Hepatology Niigata City General Hospital Department of Gastroenterology and Hepatology Tachikawa General Hospital Department of Gastroenterology and Hepatology Takeda General Hospital Department of Internal Medicine Nippon Dental University Medical Hospital Department of Internal Medicine Itoigawa General Hospital Department of Internal Medicine Uonuma Hospital Watanabe Clinic

AIM To evaluate and compare the efficacy and safety of telaprevir(TVR)-and simeprevir(SMV)-based triple therapies in elderly patients, specifically patients aged 66 years or older.METHODS The present study enrolled 112 and 76 Japanese patients with chronic hepatitis C virus genotype 1b infection who were treated with a 12-wk TVR-based or SMV-based triple therapy, respectively, followed by a dual therapy that included pegylated interferon α and ribavirin(RBV) for 12 wk. The patients were categorized into two groups according to age as follows: A younger group of patients aged ≤ 65 years old and an older group of patients aged > 65 years old. Among the patients treated with TVR-based triple therapy, 34 patients were included in the older group. The median ages were 56 years(range: 28-65 years) in the younger group and 69 years(range: 66-81 years) in the older group. Among the patients treated with SMV-based triple therapy, 39 patients were included in the older group. The median ages were 59 years(range: 36-65 years) in the younger group and 71 years(range: 66-86 years) in the older group. The clinical, biochemical and virological data were analyzed before and during treatment.RESULTS Among the patients treated with the TVR-based triple therapy, no significant difference in the sustained virological response(SVR) was found between the younger(80.8%) and older(88.2%) groups. The SVR rates for patients with the interleukin 28B(IL28B)(rs8099917) TG/GGgenotypes(73.9% and 60.0% in the younger and older groups, respectively) were significantly lower than for patients with the IL28B TT-genotype(86.3% and 92.9%, respectively). The cumulative exposure to RBV for the entire 24-wk treatment period(as a percentage of the target dose) was significantly higher in the younger group than in the older group(91.7% vs 66.7%, respectively, P < 0.01), but the cumulative exposure to TVR was not significantly different between the younger and older groups(91.6% vs 81.9%, respectively). A multivariate analysis identified the TT-genotype o

关键词： telaprevir 年老的病人丙肝病毒遗传型 1b Interleukin 28B Simeprevir

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C virus infection

引用

World Journal of Hepatology 2017年第11期9卷 551-561页

作者： Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch Division of Liver Diseases Icahn School of Medicine at Mount Sinai Icahn Medical Instititute Janssen Pharmaceuticals Com-panies Division of Janssen Scientific Affairs Inc. Genetics and Genomics Icahn School of Medicine at Mount Sinai

AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir-or boceprevir-based triple therapy(May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency viruspositive patients and patients who received a liver transplant were excluded. Factors associated with sustained virological response(SVR24) and relapse were analyzed by univariable and multivariable logistic regression as well as classification and regression trees. Fast virological response(FVR) was defined as undetectable HCV RNA at week-4(telaprevir) or week-8(boceprevir). RESULTS The median age was 57 years, 18% were black, 44% had advanced fibrosis/cirrhosis(FIB-4 ≥ 3.25). Only 42%(94/223) of patients achieved SVR24 on an intention-totreat basis. In a model that included platelets, SVR24 was associated with white race [odds ratio(OR) = 5.92, 95% confidence interval(CI): 2.34-14.96], HCV sub-genotype 1b(OR = 2.81, 95%CI: 1.45-5.44), platelet count(OR = 1.10, per x 104 cells/μL, 95%CI: 1.05-1.16), and IL28 B CC genotype(OR = 3.54, 95%CI: 1.19-10.53). Platelet counts > 135 x 103/μL were the strongest predictor of SVR by classification and regression tree. Relapse occurred in 25%(27/104) of patients with an end-oftreatment response and was associated with non-FVR(OR = 4.77, 95%CI: 1.68-13.56), HCV sub-genotype 1a(OR = 5.20; 95%CI: 1.40-18.97), and FIB-4 ≥ 3.25(OR = 2.77; 95%CI: 1.07-7.22). CONCLUSION The SVR rate was 42% with telaprevir-or boceprevirbased triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse.

关键词：持续 virologic 反应丙肝病毒恶化 telaprevir Boceprevir 三倍治疗分类和回归不利事件真实世界

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

telaprevir合聚乙二醇干扰素α及利巴韦林治疗慢性丙型肝炎疗效的荟萃分析

引用

中华肝脏病杂志 2013年第7期21卷 506-509页

作者：闫书山王轩徐栋花王平张鹏军殷杰解放军第八一医院肝脏病中心南京210029 南京医科大学第一附属医院风湿南京210029 解放军第八一医院肝脏外科南京210029 解放军第八一医院日照市人民医院急诊科南京210029 东南大学附属南京江北人民医院感染科中心南京210029

目的了解telaprevir联合聚乙二醇干扰素（Peg-IFN）α、利巴韦林对基因I型HCV感染慢性丙型肝炎患者的疗效及安全性。方法采用Meta分析方法对国外2009-2011年发表的telaprevir、Peg-IFNα及利巴韦林三联疗法治疗慢性丙型肝炎的相关研究... 详细信息

目的了解telaprevir联合聚乙二醇干扰素（Peg-IFN）α、利巴韦林对基因I型HCV感染慢性丙型肝炎患者的疗效及安全性。方法采用Meta分析方法对国外2009-2011年发表的telaprevir、Peg-IFNα及利巴韦林三联疗法治疗慢性丙型肝炎的相关研究结果进行合并效应值和异质性相关因素分析。共收集相关文献6篇，累计病例2677例。其中，telaprevir、Peg—IFNα利巴韦林治疗组（TPR组）1850例，干扰素仅、利巴韦林治疗组（PR组）827例。用Meta分析方法合并OR值或RR值及其95％可信区间。采用基于X2检验的Q检验法分析各研究的组间异质性。通过去除任意一个研究进行敏感性分析，以进一步证实研究结果的可信性。结果1850例TPR组患者中，获得快速病毒学应答（RVR）者1041例，占56．3％；获得持续病毒学应答（SVR）者1235例，占66．8％；复发率为12．1％（176／1460）。827例PR组患者中，获得RVR者58例，占7．0％；获得SVR者296例，占35．8％；复发率为32．3％（145／449）。TPR组RVR、SVR均明显高于PR组（合并OR值分别为29．83和3．97，95％CI分别为16．16～55．05和2．58～6．11，P值均〈0．01），复发率明显低于PR组（合并RR值为0．36，95％CI0．24～0．56，P〈0．01）。结论telaprevir联合Peg—IFNα、利巴韦林治疗对HCV基因I型的慢性丙型肝炎患者的疗效显著，但要注意防治不良反应。

关键词：肝炎,丙型,慢性治疗干扰素α 利巴韦林荟萃分析 telaprevir

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients

引用

World Journal of Hepatology 2014年第9期6卷 660-669页

作者： Delphine Bonnet Matthieu Guivarch Anais Palacin Laurent Alric Emilie Bérard Jean-Marc Combis Andre Jean Remy Andre Glibert Jean-Louis Payen Sophie Metivier Karl Barange Herve Desmorat Florence Nicot Florence Abravanel Internal Medicine-Digestive Department Purpan University Hospital31059 Toulouse cedex 9France UMR152 IRD Toulouse III University 31400 ToulouseFrance Department of Epidemiology Health Economics and Public HealthToulouse University Hospital31073 ToulouseFrance UMR-1027 INSERM-Toulouse III University 31062 ToulouseFrance Clinique Ambroise Pare 31300 ToulouseFrance Perpignan General Hospital 66000 PerpignanFrance Tarbes General Hospital 65000 TarbesFrance Montauban General Hospital 82000 MontaubanFrance Hepatogastroenterology-Digestive Department Purpan University Hospital31059 Toulouse cedex 9France Clinique du Parc 31078 Toulouse Cedex 4France Virology Unit INSERM U1043 31059 Toulouse cedex 9France

AIM:To assess,in a routine practice setting,the sus-tained virologic response(SVR) to telaprevir(TPV) or boceprevir(BOC) in hepatitis C virus(HCV) nullresponders or relapsers with severe liver fibrosis.METHODS:One hundred twenty-five patients were treated prospectively for 48 wk with TPV or BOC + pegylated-interferon(peg-INF) α2a + ribavirin(PR) according to standard treatment schedules without randomization.These patients were treated in routine practice settings in 10 public or private health care centers,and the data were prospectively collected.Only patients with severe liver fibrosis(Metavir scores of F3 or F4 upon liver biopsy or liver stiffness assessed by elastography),genotype 1 HCV and who were null-responders or relapsers to prior PR combination therapy were included in this study.RESULTS:The Metavir fibrosis scores were F3 in 35(28%) and F4 in 90(72%) of the patients.In total,62.9% of the patients were null-responders and 37.1% relapsers to the previous PR therapy.The overall SVR rate at 24 wk post-treatment withdrawal was 59.8%.The SVR was 65.9% in the TPV group and 44.1% in the BOC group.Independent predictive factors of an SVR included a response to previous treatment,relapsers vs null-responders [OR = 3.9;(1.4,10.6),P = 0.0084],a rapid virological response(RVR) [OR 6.9(2.6,18.2),P = 0.001] and liver stiffness lower than 21.3 kPa [OR = 8.2(2.3,29.5),P = 0.001].During treatment,63 patients(50.8%) had at least one severe adverse event(SAE) of grade 3 or 4.A multivariate analysis identified two factors associated with SAEs:female gender [OR = 2.4(1.1,5.6),P = 0.037] and a platelet count below 150 × 103/ mm3 [OR = 5.3(2.3,12.4),P ≤ 0.001].CONCLUSION:More than half of these difficult-to-treat patients achieved an SVR and had SAEs in an actual practice setting.The SVR rate was influenced by the response to previous PR treatment,the RVR and liver stiffness.

关键词： Hepatitis C virus Hepatitis C Antiviral therapy Protease inhibitors Fibroscan Liver stiffness Cirrhosis Boceprevir telaprevir Ribavirin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

引用

World Journal of Hepatology 2015年第9期7卷 1287-1296页

作者： Kerstin Herzer Angela Papadopoulos-Khn Anne Achterfeld Ali Canbay Katja Piras-Straub Andreas Paul Andreas Walker Jrg Timm Guido Gerken Department of Gastroenterology and Hepatology University Hospital Essen Department of General-Visceral and Transplantation Surgery University Hospital Essen Institute for Virology Heinrich Heine University

AIM: To characterize management of telaprevir(TVR)-based triple therapy of hepatitis C virus(HCV) reinfection after liver transplantation(LT).METHODS: We retrospectively analyzed safety and efficacy of telaprevir- based triple therapy in a single center cohort of 19 patients with HCV genotype(GT) 1 recurrence after LT, with respect to factors possibly predicting sustained viral response(SVR) or non-SVR. All patients were treated with TVR, pegylated(PEG) and ribavirine(RBV) for 12 wk followed by a dual phase with PEG/RBV for 12 wk in 7 patients and for 36 wk in 5 patients. RESULTS: In total 11/19(58%) of patients achieved a sustained response. All(11/11) SVR patients showed a rapid viral response at treatment weeks 4 and 11/14 rapid virological response(RVR) patients achieved SVR. Notably, all(7/7) patients who completed 48 wk of therapy and 80%(4/5) patients who completed 24 wk of therapy achieved SVR24. Treatment failure was significantly(P > 0.049) more frequent in GT1 a infection(5/7) compared to GT1b(3/12) infection and was associated with emergence of resistance-associated mutations in the NS3 protease domain. Bilirubin level at baseline is also related to SVR(P > 0.030). None of the patients had to discontinue treatment due to side effects. CONCLUSION: RVR, GT and bilirubin are clearly related to achievement of SVR. Providing a thorough patient selection and monitoring, a full course of TVR-based triple therapy in LT patients is feasible and achieves high SVR rates.

关键词： Liver transplantation telaprevir HepatitisC virus recurrence Predictors Hepatitis C virus therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Aplastic anemia and severe pancytopenia during treatment with peg-interferon,ribavirin and telaprevir for chronic hepatitis C

引用

World Journal of Gastroenterology 2015年第17期21卷 5421-5426页

作者： Sabela Lens Jose L Calleja Ana Campillo Jose A Carrion Teresa Broquetas Christie Perello Juan de la Revilla Zoe Marino Maria-Carlota Londono Jose M Sanchez-Tapias Alvaro Urbano-Ispizua Xavier Forns Liver Unit Hospital ClinicIDIBAPSCIBERehd08036 BarcelonaSpain Liver Unit Hospital Puerta del HierroIDIPHIMCIBERehd28222 MajadahondaMadridSpain Gastroenterology Department Hospital Reina Sofia31500 TudelaNavarraSpain Liver Unit Hospital Del MarIMIMCIBERehd08003 BarcelonaSpain Hematology Unit Hospital Clinic08036 BarcelonaSpain

telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin.Pancytopenia due to myelotoxicity caused by these drugs may occur,but severe hematological abnormalities or aplastic anemia(AA) have not been described.We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011.Among 142 cirrhotic patients receiving treatment,7 cases of severe pancytopenia(5%) were identified and three were consistent with the diagnosis of AA.Mean age was 59 years,five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver transplantation.Severe pancytopenia was diagnosed a median of 10 wk after the initiation of therapy.Three patients had pre-treatment hematological abnormalities related to splenomegaly.In six patients,antiviral treatment was interrupted at the onset of hematological abnormalities.Two patients died due to septic complications and one patient due to acute alveolar hemorrhage.The remaining patients recovered.Severe pancytopenia and especially AA,are not rare during triple therapy with telaprevir in patients with advanced liver disease.Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications.

关键词： Aplastic anemia Hepatitis C telaprevir Interferon Protease inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma

引用

World Journal of Hepatology 2013年第6期5卷 332-335页

作者： Harrys A Torres Parag Mahale Ethan D Miller Thein H Oo Catherine Frenette Ahmed O Kaseb Departments of Infectious Diseases Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Departments of Gastroenterology Hepatology and Nutrition The University of Texas MD Anderson Cancer Center Section of Benign Hematology The University of Texas MD Anderson Cancer Center Liver Transplantation Weill Cornell Medical College The Methodist Hospital Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center

The use of directacting antiviral agents (e.g. , telaprevir, boceprevir) has improved response rates in patients with hepatitis C virus (HCV) genotype 1 infections. Substantial number of drug-drug interactions are anticipated with the use of telaprevir, a cytochrome P450 3A and P-glycoprotein substrate and inhibitor. Herein we describe a patient with HCV-associated hepatocellular carcinoma treated simultaneously with a telaprevir-containing regimen and localized chemo-therapy (transcatheter arterial chemoembolization) with doxorubicin. No clinically relevant interactions or adverse events developed while on antiviral therapy.

关键词： Hepatitis C virus Cancer Hepatocellular carcinoma Transcatheter arterial chemoembolization telaprevir Interactions

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience

引用

World Journal of Hepatology 2016年第22期8卷 949-956页

作者： Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri Giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina Barbara Guerrera Roberto Gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella Guido Piai Antonio Picardi Paola Pierri Grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra Gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone Depart-ment of Medicine Center for Liver Diseases "Buon Consiglio" -Fatebenefratelli Hospital Internal Medicine Unit Second University of Naples VI Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of Gastro- enterology Casa Sollievo Sofferenza Hospital IRCCS Division of Infectious Diseases Belcolle Hospital IX Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Clinical of Infectious Disease University of Sassari Infectious Disease IRCCS San Matteo Division of Infectious Diseases and Liver Unit "G. Iazzolino" Hospital Division of Infectious Diseases "Annunziata" Hospital Depart-ment of Internal Medicine Umberto I Hospital Internal Medicine Ospedale Evangelico Villa Betania Division of Gastroenterology IRCCS "S.de Bellis" Hospital Internal Medicine Unit Pescara-Penne Hospital Gastroenterology Unit Marcianise Hospital Liver Unit AORN Cardarelli Liver Unit Policlinico "Mater Domini" Service of Medical Day Hospital "Rummo" Hospital Internal Medicine Regina Margherita Hospital Division of Gastroenterology "Annunziata" Hospital Infectious Disease Matera Hospital First Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of Infectious Diseases AO Melacrino- Bianchi-Morelli Infectious and Tropical Disease Policlinico Umberto I Division of Infectious Disease Maria SS Addolorata Hospital Division of Infectious Diseases S. Anna and S. Sebastiano Hospital Outpatients Service for Liver Diseases "Loreto Crispi" Hospital V Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Department of Medical Surgical Neurological Geriatric and Metabolic Sciences Second Univer-sity of Naples Liver Unit Policlinico Casilino Medicine and Health Unit for Prisoners Belcolle Hospital Internal Medicine Unit "Ascalesi" Hospital Gastrointestinal and Liver Department National Institute for Health Migration and Poverty Liver Unit Azienda Ospedaliera San Camillo Forlanini VII Division of Infectious Diseases

AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean body mass index 25.6(range 16-39); genotype 1b(79.4%); diagnosis of cirrhosis(38.2%); and fibrosis F3/4(71.2%). The following drugs were used: telaprevir(66.2%) and PEG-IFN-alpha2a(67.6%). Patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin.

关键词： Boceprevir telaprevir Chronic hepatitis Antiviral therapy Peg-interferon Ribavirin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching

引用

World Journal of Hepatology 2015年第28期7卷 2841-2848页

作者： Hideki Fujii Takeshi Nishimura Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Yoshio Sumida Hironori Mitsuyoshi Chihiro Yokomizo Saiyu Tanaka Hiroki Ishikawa Kenichi Nishioji Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Takayuki Takeuchi Toshihide Shima Yoshihiko Sawa Masahito Minami Kohichiroh Yasui Yoshito Itoh Department of Molecular Gastroenterology and Hepatology Kyoto Prefectural University of Medicine Department of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Department of Gastroenterology and Hepatology North Medical Center Kyoto Prefectural University of Medicine Department of Gastroenterology Osaka General Hospital of West Japan Railway Company Center for Digestive and Liver Diseases Nara City Hospital Department of Gastroenterology and Hepatology Omihachiman Community Medical Center Health Care Division Kyoto Second Red Cross Hospital Department of Gastroenterology Otsu Municipal Hospital Department of Gastroenterology Matsushita Memorial Hospital Higashiomicity Notogawa Hospital Center of Gastroenterology and Hepatology Saiseikai Suita Hospital Department of Internal Medicine Aiseikai Yamashina Hospital

AIM: To compare efficacy of telaprevir(TVR) and simeprevir(SMV) combined with pegylated interferon(PEG-IFN) and ribavirin(RBV) while treating chronic hepatitis C(CHC). METHODS: In all, 306 CHC patients were included in this study. There were 159 patients in the TVR combination therapy group and 147 patients in the SMV combination therapy group. To evaluate pretreatment factors contributing to sustained virological response at 12 wk(SVR12), univariate and multivariate analyses were performed in TVR and SMV groups. To adjust for patient background between TVR and SMV groups, propensity score matching was performed. Virological response during treatment and SVR12 were evaluated.RESULTS: Overall rates of SVR12 [undetectable serum hepatitis C virus(HCV) RNA levels] were 79.2% and 69.4% in TVR and SMV groups, respectively. Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B(IL28B) genotype(rs8099917), and poorer response to previous PEG-IFN and RBV treatment. Propensity score matching was performed to adjust for backgrounds(n = 104) and demonstrated SVR12 rates of 74.0% and 73.1% in the TVR and SMV groups, respectively. In the TVR group, discontinuation rates were higher because of adverse events; however, breakthrough and nonresponse was more frequent in the in SMV group. Multivariate analysis revealed IL28 B genotype(rs8099917) as the only independent predictive factor of SVR12 in both groups.CONCLUSION: SVR12 rates were almost identical following propensity score matching.

关键词： Chronic hepatitis C Combination therapy Pegylated interferon Simeprevir telaprevir Propensityscore matching Protease inhibitor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

治疗丙型肝炎的药物——telaprevir

引用

药学进展 2008年第3期32卷 136-138页

作者：孙大柠

已经完成的Ⅱ期临床实验结果表明,Vertex制药公司率先研发的telaprevir(曾用代号VX-950;LY-570310;MP-424)对慢性丙型肝炎患者有良好的治疗效果.

关键词： telaprevir 丙型肝炎抗病毒药

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：